Clinical Trials Logo

Kasabach Merritt Phenomenon clinical trials

View clinical trials related to Kasabach Merritt Phenomenon.

Filter by:
  • None
  • Page 1

NCT ID: NCT03188068 Completed - Clinical trials for Kaposiform Hemangioendothelioma

Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma

Start date: June 1, 2017
Phase: Phase 2
Study type: Interventional

Kaposiform hemangioendothelioma (KHE) is a rare vascular neoplasm that occurs predominantly in infancy or early childhood. KHE has a nearly equal sex ratio. The annual incidence of KHE has been estimated at 0.071 per 100,000 children. KHE presents with intermediate-malignant and locally aggressive characteristics but without distant metastases. This pilot trial studies sirolimus versus sirolimus plus pednisolone in treating patients diagnosed with kaposiform hemangioendothelioma (KHE) and Kasabach-Merritt phenomemon (KMP) that cannot be removed by surgery. The purpose of this study is to compare the efficacy and safety of orally administered sirolimus versus sirolimus plus pednisolone in the treatment of KHE associated with KMP.